Literature DB >> 15708695

Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders.

Jozef Masura1, Pavol Gavora, Tomaz Podnar.   

Abstract

OBJECTIVES: The aim of this study was to assess long-term results of percutaneous closure of secundum-type atrial septal defect (ASD II) using Amplatzer septal occluders (ASO).
BACKGROUND: Only immediate-, short-, and intermediate-term results of ASO implantation are known so far.
METHODS: Between September 1995 and January 2000, 151 patients underwent a successful percutaneous closure of ASD II in our institution. All were included in the present study and were followed up until September 2004.
RESULTS: This group of patients was followed up from 56 to 108 months (median 78 months). The mean stretched defect diameter was 15.9 +/- 4.8 mm. There were no deaths or significant complications during the study. At three years of follow-up, all defects were completely closed and remained closed thereafter.
CONCLUSIONS: Since the first human implantations in September 1995, the Amplatzer septal occluder proved as a safe and effective device for percutaneous closure of ASD II.

Entities:  

Mesh:

Year:  2005        PMID: 15708695     DOI: 10.1016/j.jacc.2004.10.066

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  46 in total

Review 1.  Atrial septum defect closure device in a beating heart, from the perspective of a researcher in artificial organs.

Authors:  Yasuko Tomizawa
Journal:  J Artif Organs       Date:  2012-06-23       Impact factor: 1.731

2.  Late bacterial endocarditis of an Amplatzer atrial septal device.

Authors:  Bhavith Aruni; Ali Sharifian; Paula Eryazici; Cesar J Herrera
Journal:  Indian Heart J       Date:  2013-07-24

3.  Histopathological workup of an Amplatzer atrial septal defect occluder after surgical removal.

Authors:  Matthias Sigler; Christian Jux; Peter Ewert
Journal:  Pediatr Cardiol       Date:  2006-10-09       Impact factor: 1.655

4.  Ceraflex versus Amplatzer occluder for secundum atrial septal defect closure. Multicenter clinical experience.

Authors:  M A Astarcioglu; M Kalcik; T Sen; A C Aykan; T Gokdeniz; O M Gursoy; S Karakoyun; S Kulahcioglu; S Gunduz; C Kilit; M Oylumlu; B Amasyali
Journal:  Herz       Date:  2015-02-08       Impact factor: 1.443

5.  Unusual atrial septal anatomy resulting in an interatrial chamber: the true triatrial heart?

Authors:  A J Javois; D A Roberson
Journal:  Pediatr Cardiol       Date:  2007 May-Jun       Impact factor: 1.655

6.  Right-sided pulmonary venous obstruction between a right aortic arch and an amplatzer septal occlusion device following closure of a secundum atrial septal defect.

Authors:  Kevin Hill; Karla Christian; Ann Kavanaugh-McHugh; Thomas Doyle
Journal:  Pediatr Cardiol       Date:  2009-04-15       Impact factor: 1.655

7.  Atrial septal defects type II: noninvasive evaluation of patients before implantation of an Amplatzer Septal Occluder and on follow-up by magnetic resonance imaging compared with TEE and invasive measurement.

Authors:  Christoph Weber; Michael Weber; Okan Ekinci; Thomas Neumann; Anja Deetjen; Andreas Rolf; Gerhard Adam; Christian W Hamm; Thorsten Dill
Journal:  Eur Radiol       Date:  2008-06-21       Impact factor: 5.315

8.  Assessment of atrial septal defect size and residual rim using real-time 3D transesophageal echocardiography.

Authors:  Kyoko Kaku; Masaaki Takeuchi; Lissa Sugeng; Joseph A Lodato; Hiromi Nakai; Lynn Weinert; Kyoko Otani; Hidetoshi Yoshitani; Nobuhiko Haruki; Ziyad M Hijazi; Yutaka Otsuji; Roberto M Lang
Journal:  J Echocardiogr       Date:  2009-07-14

Review 9.  The causes of Charcot-Marie-Tooth disease.

Authors:  P Young; U Suter
Journal:  Cell Mol Life Sci       Date:  2003-12       Impact factor: 9.261

10.  Cardiac remodeling and effects on exercise capacity after interventional closure of atrial septal defects in different adult age groups.

Authors:  Smita Jategaonkar; Werner Scholtz; Henning Schmidt; Dieter Fassbender; Dieter Horstkotte
Journal:  Clin Res Cardiol       Date:  2010-03       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.